Research Center: National Jewish Health
Location: 1400 Jackson St, Denver, CO 80206
Lead Researcher: Donald Leung, MD, PhD
IRB: This study has been reviewed and approved by the BRANY (Biomedical Research Alliance of New York) IRB

Managing food allergies can be stressful—for both kids and parents. Constant concerns about allergic reactions and limited treatment options can make everyday life feel overwhelming.

Researchers are exploring whether Xolair (omalizumab)—a medication already used for allergic conditions—might help reduce food allergy symptoms and related skin issues.

If your child is between 1 and 18 years old, they may be able to join this study. Participants will receive Xolair at no cost, and your family’s involvement could help researchers learn more about how allergy treatments affect the skin barrier.

Help move allergy research forward. Learn more and see if your child qualifies today.

• Participants will receive Xolair (omalizumab) for food allergies at no cost.
• Participants will be compensated per study visit.
• Participants may experience improvements in food allergy symptoms and related skin conditions.
• Participants will be contributing valuable information that may benefit individuals with food allergies in the future.
• Participants will be helping to advance medical research on allergy treatments.

• You will receive a detailed outline of all details of the study, including treatment, risks, and procedures, and you will be given the chance to ask study staff questions before you decide whether to participate.
• If you decide to participate in the study and later feel that you no longer wish to be part of it, you can withdraw at any time
• Your records relating to this study and any other information received will be kept strictly confidential, except as required by the law.

Eligible:

• Children aged 1-18 who are diagnosed with or who have experienced a food sensitization (positive allergy test or reaction) to peanut, hen’s egg, tree nuts, sesame seed, cow’s milk, wheat, or soy within the past year.
• Must be willing to be trained on the proper use of an epinephrine autoinjector and to have it available at all times during the study.
• Must be able to read and speak English.
• Must be able to attend 6 study visits at the research site over approximately 5 months

Ineligible:

• Must not have a history of severe anaphylaxis requiring intubation or neurological compromise.
• Must not have a history of reaction to omalizumab.
• Must not have a history of serious life-threatening reactions to tape or adhesives.

National Jewish Health
National Jewish Health is the leading respiratory hospital in the nation. Founded in 1899 as a nonprofit hospital, National Jewish Health today is the only facility in the world dedicated exclusively to groundbreaking medical research and treatment of children and adults with respiratory, cardiac, immune, and related disorders. Patients and families come to National Jewish Health from around the world to receive cutting-edge, comprehensive, coordinated care.